Lisdexamfetamine (Vyvanse) Withdrawal in Children with Orofacial Cleft and Attention-Deficit/Hyperactivity Disorder

Stimulants are the first line of therapy for attention-deficit/hyperactivity disorder (ADHD) in children 6 years and older. Vyvanse is a long acting prodrug stimulant with well-established safety, tolerability and efficacy, when compared to other stimulants such as amphetamine and methylphenidate, and non-stimulants such as atomoxetine, guanfacine, and clonidine. Treatment related adverse events for stimulant drugs in all age groups have been reported in great detail, but there is limited data available in the literature regarding withdrawal symptoms from acute cessation or dose reduction in children.

Source: The British Journal of Oral and Maxillofacial Surgery - November 30, 2019 Category: ENT & OMF Authors: Stavan Patel, Curtis Schmidt, Adam Blancher, G.E. Ghali Tags: P58 Source Type: research